What Is the Difference Between Leukocyte-Rich and Leukocyte-Poor PRP?
Published November 16, 2026
Protocol: 6 steps in this guide
The difference is the number of white blood cells (leukocytes) in the preparation. Leukocyte-rich PRP (LR-PRP) has more of them than the patient’s own blood; leukocyte-poor PRP (LP-PRP) has fewer. Which one a clinic produces depends mainly on which layers of spun blood are collected. As for which works better, the research does not give a single answer: recent analyses in knee osteoarthritis point in different directions, and the evidence is weak enough that neither type can be called the winner across conditions.
White blood cells versus platelets
Platelets are the reason PRP exists: they carry the growth factors the preparation is meant to concentrate. White blood cells are a separate component that comes along to a greater or lesser degree.
The American Academy of Orthopaedic Surgeons gives a simple working definition on its patient page on platelet-rich plasma: leukocyte-rich PRP “contains a white blood cell count greater than 100% of a whole blood sample,” and leukocyte-poor PRP “contains a white blood cell count of less than 100% of a whole blood sample.” In other words, LR-PRP has more white cells than the patient’s own blood; LP-PRP has fewer. AAOS adds that “the effectiveness of leukocyte rich PRP vs. leukocyte poor PRP (the two types of PRP mixtures) has not yet been determined.”
| Feature | Leukocyte-rich PRP | Leukocyte-poor PRP |
|---|---|---|
| White blood cell count (AAOS definition) | Above whole-blood level | Below whole-blood level |
| How it is made (methods review) | Whole buffy coat collected, with a few red cells | Upper layer and only the surface of the buffy coat collected |
| Proven better overall? | No | No |
How separation changes leukocyte fraction
When blood is spun, a thin middle layer called the buffy coat forms between the plasma and the red cells. A methods review in the Journal of Cutaneous and Aesthetic Surgery, Principles and Methods of Preparation of Platelet-Rich Plasma, describes this layer as “rich in WBCs” and explains that for pure (leukocyte-poor) PRP the upper layer and superficial buffy coat are transferred, while for leukocyte-rich PRP “the entire layer of buffy coat and few RBCs are transferred.” The same review notes that commercial systems produce “suspensions of different concentration of platelets and leucocytes.”
A 2025 review in Acta Biomaterialia by Rath and colleagues, Platelet-rich plasma – A comprehensive review of isolation, activation, and application, lists “platelet and leukocyte content” among the variables that complicate standardization of platelet-rich products. Two products labeled “leukocyte-poor” may still differ from each other. The full preparation process is explained in how platelet-rich plasma is made from a blood sample.
Why white blood cells might help or harm
White blood cells are part of the immune response, which is why their inclusion is a question at all. A 2024 multispecialty guideline in the Journal of Pain Research, Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain, describes “debate on the utility of including leukocytes in PRP preparations due to potential for secreted cytokines to cause inflammation,” adds that such preparations “may also have potential in preventing infection and improving healing,” and concludes that the optimal leukocyte concentration “is controversial and has not been well-established in vivo.” AAOS similarly states that the relative effectiveness of the two mixtures “has not yet been determined.” The useful question is what happens in patients, and there the evidence is condition-specific and mixed.
A 2020 review in the Journal of Orthopaedic Research, Tendon and Ligament Healing and Current Approaches to Tendon and Ligament Regeneration, describes the pattern of use rather than proof of benefit: “In general, leukocyte-poor PRP is used for osteoarthritic treatment, while leukocyte-rich PRP is used for tendonitis and similar conditions.” How a preparation is used is not evidence that it is the better choice.
Condition-specific study observations
In knee osteoarthritis, three recent analyses illustrate why no winner has been declared:
| Analysis | Comparison | Leukocyte finding | Caveat |
|---|---|---|---|
| Delgado and colleagues, Knee Surgery, Sports Traumatology, Arthroscopy (2026) | PRP vs placebo, 20 trials | Leukocyte-rich PRP associated with better knee function at 6 months | Very low certainty; PRP type and concentration factor were correlated; no moderator explained results at 12 months |
| Abduljabbar and colleagues, Journal of ISAKOS (2026) | PRP vs hyaluronic acid, 28 trials | Larger treatment effects with leukocyte-poor PRP | Effect modifier in a pooled analysis with very high heterogeneity |
| Zhong and colleagues, Arthroscopy (2026) | PRP vs hyaluronic acid, 21 trials | Leukocyte-rich, high-concentration and activated PRP associated with better 12-month outcomes | Subgroup finding |
The two hyaluronic acid comparisons are Abduljabbar and colleagues, Platelet-rich plasma provides greater pain relief and functional improvement than hyaluronic acid for knee osteoarthritis, and Zhong and colleagues, “Platelet-Rich Plasma Provides Small but Superior Short-term Pain Relief and Functional Improvement Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis.” These analyses point in opposite directions, and all three rely on comparisons between trials rather than head-to-head tests of the two preparations. The authors of the Delgado meta-regression call their results “hypothesis-generating rather than definitive evidence supporting specific PRP formulations.” The hip offers a separate example: a 2026 meta-analysis of PRP versus hyaluronic acid for hip osteoarthritis, Comparison of Clinical Efficiency and Safety in Pain Research and Management, found that leukocyte-poor PRP produced a significant pain improvement at six months while the leukocyte-rich subgroup did not reach significance.
Tendon conditions have their own evidence, covered in the posts on tennis elbow and chronic Achilles tendinopathy, and a knee result should not be carried over to them.
What recent meta-analyses mean for knee osteoarthritis
For knee arthritis specifically, the leukocyte question is open. One placebo-controlled analysis favors leukocyte-rich preparations at six months, one hyaluronic acid comparison favors leukocyte-poor preparations, and another favors leukocyte-rich preparations at twelve months. With very low certainty in the placebo-controlled analysis, correlated product features and comparisons made between trials rather than within them, none of these can tell a patient which preparation will work better for them. Overall knee evidence is covered in what the evidence says about PRP for knee osteoarthritis, and the hyaluronic acid comparison in how PRP and hyaluronic acid compare for knee osteoarthritis function.
Questions about product characterization
Because labels vary, a practical step is to ask what is actually in the syringe:
- Is this preparation leukocyte-rich or leukocyte-poor, and how does the clinic know? A measured white cell count is more informative than a device label.
- Why this type for this condition? The answer should refer to the condition being treated, not to a general claim that one type is better.
- What is the platelet concentration? Concentration and leukocyte content are linked in some systems, which is one reason studies struggle to separate their effects; see whether platelet concentration changes PRP treatment outcomes.
Neither type is always harmful, and neither is always better. The choice for a particular injury rests with the treating clinician, who should be able to explain it.
Leukocyte-rich and leukocyte-poor PRP differ in white blood cell content because of which blood layers are collected, and current studies conflict on which is better, so the preparation should be described and justified for each condition rather than assumed superior.
Cells linked to this one
This guide leads on to
- B1 How Is Platelet-Rich Plasma Made From a Blood Sample?
- C2 Is PRP Effective for Tennis Elbow?
- C3 Does PRP Help Chronic Achilles Tendinopathy?
- C1 What Does the Evidence Say About PRP for Knee Osteoarthritis?
- H2 PRP vs. Hyaluronic Acid for Knee Osteoarthritis: How Do Functional Outcomes Compare?
- B3 Does Platelet Concentration Change PRP Treatment Outcomes?
Guides that lead here
- C7 How Effective Is PRP for Hip Osteoarthritis According to Clinical Studies?
- A1 What Are Orthobiologics, and How Are They Classified?
- C9 Can PRP Help a Torn Meniscus Heal Without Surgery?
- B4 What Is PRP Activation, and When Is It Used?
- C11 Can PRP Improve Healing After Rotator Cuff Repair?
- C4 Can PRP Improve Patellar Tendinopathy?
- D3 How Is A2M Concentrated From a Patient's Blood?
- C5 What Is Known About PRP for Rotator Cuff Tendinopathy?
Add a remark